Leaderboards/Melanoma and MAPK Pathways

Melanoma and MAPK Pathways

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Md Entaz Bahar
Gyeongsang National University
2
David Gritsch
Harvard University
3
James Cregg
Revolution Medicines (United States)
4
Haozhen Lv
Chinese Academy of Medical Sciences & Peking Union Medical College
5
Erica C. Nakajima
AstraZeneca (Netherlands)
6
Abhineet Ram
University of California, Davis
7
Simone Lubrano
University of California San Diego
8
Florian Uhlitz
Immunai (United States)
9
Zhongwei Mao
King Center
10
Juliana A. Martinez Fiesco
Frederick National Laboratory for Cancer Research

Papers

1
Publication in Journal of Medicinal Chemistry (2025) [72 citations, W4408247136]
Journal of Medicinal Chemistry|2025
72 cit.
2
Publication in Journal of Medicinal Chemistry (2025) [40 citations, W4407898113]
Journal of Medicinal Chemistry|2025
40 cit.
3
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
Cancer Cell|2025
34 cit.
4
14-3-3 binding maintains the Parkinson’s associated kinase LRRK2 in an inactive state
Nature Communications|2025
11 cit.
5
Role of hippo pathway and cuproptosis-related genes in immune infiltration and prognosis of skin cutaneous melanoma
Frontiers in Pharmacology|2024
9 cit.
6
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group
JCO Precision Oncology|2024
6 cit.
7
Deciphering the history of ERK activity from fixed-cell immunofluorescence measurements
Nature Communications|2025
5 cit.
8
Publication in Cancer Research (2024) [2 citations, W4393089000]
Cancer Research|2024
2 cit.
9
Publication in Journal of Biological Chemistry (2025) [1 citation, W4414121982]
Journal of Biological Chemistry|2025
1 cit.
10
Unraveling Resistance Mechanisms to Gαq Pathway Inhibition in Uveal Melanoma: Insights from Signaling-Activation Library Screening
Cancers|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Jason J. Luke
University of Chicago
2
Poulikos I. Poulikakos
Icahn School of Medicine at Mount Sinai
3
Lingzhi Wang
Jishou University
4
Zhihao Wu
Hainan Medical University
5
David Wildes
Revolution Medicines (United States)
6
Zexian Fu
Hebei University of Engineering
7
Kwan Ho Tang
AstraZeneca (Netherlands)
8
Arvin C. Dar
Memorial Sloan Kettering Cancer Center
9
Bahaa G. M. Youssif
Assiut University
10
Cory M. Johannessen
Novartis (China)

Papers

1
Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Clinical Cancer Research|2023
145 cit.
2
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Nature Medicine|2023
128 cit.
3
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
Journal of Clinical Oncology|2024
96 cit.
4
Optimization and SAR investigation of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as EGFR and BRAFV600E dual inhibitors with potent antiproliferative and antioxidant activities
Bioorganic Chemistry|2022
59 cit.
5
New 1,3,4‐oxadiazoles linked with the 1,2,3‐triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase
Archiv der Pharmazie|2022
55 cit.
6
Drug-induced lactate confers ferroptosis resistance via p38-SGK1-NEDD4L-dependent upregulation of GPX4 in NSCLC cells
Cell Death Discovery|2023
53 cit.
7
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Clinical Cancer Research|2022
48 cit.
8
Novel piperine-carboximidamide hybrids: design, synthesis, and antiproliferative activity via a multi-targeted inhibitory pathway
Journal of Enzyme Inhibition and Medicinal Chemistry|2022
48 cit.
9
Design, synthesis, and antiproliferative properties of new 1,2,3-triazole-carboximidamide derivatives as dual EGFR/VEGFR-2 inhibitors
Journal of Molecular Structure|2023
48 cit.
10
Synthesis and Biological Evaluation of Indole-2-Carboxamides with Potent Apoptotic Antiproliferative Activity as EGFR/CDK2 Dual Inhibitors
Pharmaceuticals|2022
43 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Roger J. Davis
University of Massachusetts Chan Medical School
2
Philip Cohen
MRC Protein Phosphorylation and Ubiquitylation Unit
3
Grant A. McArthur
The University of Melbourne
4
P. Andrew Futreal
Wellcome Sanger Institute
5
Levi A. Garraway
Broad Institute
6
Michael Karin
Discovery Institute
7
Richard Marais
Macclesfield College
8
Dirk Schadendorf
National Center for Tumor Diseases
9
Michael E. Greenberg
Harvard University
10
Antoni Ribas
University of California, Los Angeles

Papers

1
Mutations of the BRAF gene in human cancer
Nature|2002
10.7k cit.
2
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Nature|2012
8.5k cit.
3
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
New England Journal of Medicine|2011
7.7k cit.
4
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Nature|2014
6.6k cit.
5
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Cell|1999
6.6k cit.
6
Pembrolizumab versus Ipilimumab in Advanced Melanoma
New England Journal of Medicine|2015
5.8k cit.
7
Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery
Cell|1997
5.7k cit.
8
Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis
Science|1995
5.3k cit.
9
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Science|2016
5.2k cit.
10
Specificity and mechanism of action of some commonly used protein kinase inhibitors
Biochemical Journal|2000
4.1k cit.

Reagents for Melanoma and MAPK Pathways

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 66

beta-Catenin (D10A8) Rabbit Monoclonal Antibody (PE Conjugate)

Cited in 20 papers
#14903$471
View Evidence →
Cell Signaling TechnologyEvidence 66

COX IV (3E11) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

Cited in 17 papers
#4853$465
View Evidence →
Bio-RadEvidence 63

RABBIT ANTI RAT MEK 5 (pSer311/Thr315)

Cited in 17 papers
#AHP1302
View Evidence →

🌟 All-Time

Most validated

RocheEvidence 75

VENTANA® anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody

Cited in 30 papers
#760-5095 (also 08033706001)
View Evidence →
MedChemExpressEvidence 77

Phospho-BRAF (Thr401) Antibody

Cited in 24 papers
#HY-P80794
View Evidence →
MedChemExpressEvidence 72

BRAF Antibody

Cited in 24 papers
#HY-P80572
View Evidence →